Analyzing CohBar (NASDAQ:CWBR) and Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ:KROS) and CohBar (NASDAQ:CWBR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Earnings & Valuation

This table compares Keros Therapeutics and CohBar”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$150,000.00	15,198.10	-$152.99 million	($5.13)	-11.84
CohBar	N/A	N/A	-$12.18 million	($4.36)	-0.11

CohBar has lower revenue, but higher earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than CohBar, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Keros Therapeutics and CohBar’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-62,012.55%	-44.73%	-41.06%
CohBar	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Keros Therapeutics and CohBar, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	0	0	11	0	3.00
CohBar	0	0	0	0	N/A

Keros Therapeutics currently has a consensus target price of $89.11, indicating a potential upside of 46.66%. Given Keros Therapeutics’ higher possible upside, research analysts clearly believe Keros Therapeutics is more favorable than CohBar.

Insider and Institutional Ownership

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 2.5% of CohBar shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by company insiders. Comparatively, 6.5% of CohBar shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Keros Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, CohBar has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Summary

CohBar beats Keros Therapeutics on 7 of the 12 factors compared between the two stocks.

About Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

About CohBar

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.